Influences of Gastrodin on CGRP， NO and ET1 Expression in Peripheral Blood of Migraine Patients

OBJECTIVE To observe the clinical effect of gastrodin in treating migraine and its influences on serum calcitonin gene related peptide(CGRP)， nitric oxide(NO) and endothelin1 (ET1) expression. METHODS 80 cases with migraine were randomly divided into the treatment group and control group. Patients in the treatment group were given routine treatment plus 10 mg flunarizine every night. While those in the control group were given the routine treatment plus one-time injection of 600mg gastrodin per day. The peripheral venous bloods of the above patients together with 35 healthy people were collected before and 10 days after treatment. ①VAS grade changes of both groups and also the curative rates were observed and evaluated. ②ELISA method was adopted to compare the serum CGRP， NO and ET1 expression of patients. RESULTS ①After treatment， the VAS grades of both groups were reduced and the treatment group was lower than the control group(P<0.05). Also the curative rate of the treatment group was notably higher than that of the control group(P<0.05); ②No evident differences of CGRP， NO and ET1 expression were noticed between the two groups before treatment(P>0.05)， while these expression were much higher than those of the healthy group(P<0.01); ③CGRP， NO and ET1 expressions of both groups were detected to have been declined on the tenth day after treatment(P<0.01)， and the treatment group was much lower than the control group(P<0.01). CONCLUSION Gastrodin is efficient in improving clinical symptoms of patients with migraine and reducing the expression of CGRP， NO and ET1 in the serum， which might be one of the mechanisms for its effective role in relieving migraine.